BNT162b2疫苗接种后抗RBD IgG滴度长期下降不反映SARS-CoV-2中和生物活性丧失
该研究在57名未感染新冠的医护人员中,于接种BNT162b2疫苗后6个月内多个时间点检测抗RBD IgG和替代病毒中和试验。结果显示抗RBD IgG均值从第二剂后30天的2583 BAU/mL显著降至6个月时的320.4 BAU/mL,但中和百分比仍维持在82%,且抗RBD IgG绝对值预测高中和活性的阈值随时间变化,提示其并非中和活性的可靠标志。
要点
- 接种BNT162b2后6个月抗RBD IgG均值显著下降,但中和活性在几乎所有个体中维持。
- 抗RBD IgG绝对值不能可靠预测中和生物活性,预测阈值随时间变化。
- 临床解读抗体结果时需结合接种时间,避免仅凭IgG水平判断保护力。
核心结论
- 接种BNT162b2疫苗后6个月,抗RBD IgG均值明显下降,但几乎全部个体仍维持高中和生物活性。
- 抗RBD IgG绝对值是中和生物活性的差标志。
研究设计与样本
- 前瞻性队列研究,纳入57名未感染SARS-CoV-2的医护人员,接种BNT162b2疫苗。
- 在接种后6个月内多个时间点进行抗RBD IgG免疫检测和替代病毒中和试验(sVNT)。
主要发现
- 抗RBD IgG均值(范围)在T1(首剂后21天)为294.7(11.6-1554)BAU/mL,T2(第二剂后30天)为2583(398-8391)BAU/mL,T3(T0后180天)为320.4(42.3-1134)BAU/mL。
- 中和百分比均值(范围)在T1为24(0-76)%,T2为86(59-96)%,T3为82(52-99)%。
- 抗RBD IgG值与中和百分比在T2和T3呈正相关,但预测中和百分比>60%的抗RBD IgG阈值在T2和T3分别为594 BAU/mL和108 BAU/mL。
关键数值与推荐
- 抗RBD IgG预测中和百分比>60%的阈值在第二剂后30天为594 BAU/mL,在首剂后180天为108 BAU/mL。
临床怎么用
- 解读新冠疫苗后抗体检测时,应结合接种后时间,不应仅凭抗RBD IgG绝对值推断中和保护力。
- 抗RBD IgG动态下降不必然意味着中和生物活性丧失,需谨慎解释长期随访抗体结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Long-term kinetics of anti-RBD IgG and neutralizing antibodies were analyzed in a cohort of COVID-19 naïve health care workers (HCW) undergoing SARS-CoV-2 vaccination. METHODS: An anti-RBD IgG immunoassay and a surrogate virus neutralization test (sVNT) were performed at different time points up to 6 months after vaccination in 57 HCWs. Values of anti-RBD IgG predicting an high neutralizing bioactivity (>60%) were also calculated. RESULTS: Mean (range) values of anti-RBD IgG were 294.7 (11.6-1554), 2583 (398-8391), 320.4 (42.3-1134) BAU/mL at T1 (21 days after the 1st dose [T0]), T2 (30 days after the 2nd dose) and T3 (+180 days after T0), respectively. Mean (range) percentages of neutralization (NS%) were 24 (0-76), 86 (59-96) and 82 (52-99) at T1, T2 and T3, respectively. Anti-RBD IgG values and NS% were positively correlated at T2 and T3 while anti-RBD IgG value predicting a NS% > 60 markedly differed at T2 and T3 (594 vs. 108 BAU/mL, respectively). CONCLUSION: While a high neutralizing bioactivity was maintained at least 6 months after vaccination in almost all individuals, the mean values of anti-RBD-IgG showed a marked decline at 6 months. The absolute value of anti-RBD IgG is a poor marker of neutralizing bioactivity.
引用
- Malipiero G, D'Agaro P, Segat L, et al. Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2. Clin Chim Acta. 2021. PMID: 34843705. doi:10.1016/j.cca.2021.11.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。